Clinical Trials Logo

Clinical Trial Summary

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).


Clinical Trial Description

Single-blind, randomized (1:1) pragmatic trial comparing Beta-Blocker therapy versus Calcium Channel Blocker therapy in older adults with symptomatic SIHD and MCC with plans to initiate medical treatment with anti-anginal therapy. Study Aims Aim 1: To compare the effectiveness of anti-anginal medications to improve the symptoms, function, and quality of life among older adults with multiple chronic conditions presenting with stable angina. Aim 2: To compare the tolerability and safety of commonly used anti-anginal medications in older adults with multiple chronic conditions presenting with stable angina. Aim 3 (Exploratory): To compare the long-term effectiveness and safety of specific anti-anginal medicine treatment approaches in older adults with multiple chronic conditions presenting with stable angina. LIVEBETTER consists of 4 study visits during the 12-month follow-up period. Visits are comprised of an interview, six-minute walk, and medical record review. Medication dose and administration will be addressed as part of routine clinical care. The importance of the knowledge gained includes the following: 1. LIVEBETTER will produce randomized contemporary data on the safety and efficacy of BBs vs CCBs with the goal of filling that gap of evidence in the guidelines and informing clinical practice. 2. LIVEBETTER will generate data on the quality of life, symptomatic, and functional outcomes most pertinent to older adults with multiple chronic conditions and stable angina. 3. LIVEBETTER will provide the first quantitative data on caregiver burden in older adults with stable angina. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05786417
Study type Interventional
Source Yale University
Contact Michael Nanna, MD
Phone (888) 683-0865
Email livebetter-trial@yale.edu
Status Recruiting
Phase Phase 4
Start date May 10, 2023
Completion date May 30, 2027

See also
  Status Clinical Trial Phase
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Withdrawn NCT03134105 - A Wearable EducAtional Intervention to REduce Angina N/A
Completed NCT02832115 - Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention Phase 4
Completed NCT02265796 - Ranolazine Among Unrevascularized Chronic Stable Angina Patients Phase 2
Terminated NCT00221182 - Stem Cell Study for Patients With Heart Disease Phase 1/Phase 2
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Recruiting NCT01214499 - Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina Phase 2
Terminated NCT01285297 - Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction N/A
Withdrawn NCT00774891 - Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography N/A
Completed NCT02707783 - Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina
Completed NCT02065102 - Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty N/A
Completed NCT00946725 - To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg Phase 1
Recruiting NCT02439541 - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Withdrawn NCT00657514 - Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Phase 4
Recruiting NCT01361659 - Shockwave Treatment for Advanced Angina in Maastricht N/A
Withdrawn NCT02507050 - Ivabradine and Post-revascularisation Microcirculatory Dysfunction Phase 4
Active, not recruiting NCT02468960 - Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS) N/A
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A
Completed NCT00824005 - Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) Phase 2